Pharmaceutical Localization Review
A data-driven guide for EHS managers and regulatory affairs teams evaluating pharmaceutical translation providers. Published metrics, client track records, and evaluation criteria for regulatory content.
See evaluation criteria ↓Generic RFP templates miss what matters for regulatory content. These are the criteria that predict quality outcomes in pharmaceutical translation.
Ask for their terminology consistency rate across deliverables. Anything below 95% means approved terms are being used inconsistently across your SmPCs, PILs, and labeling. Inconsistent terminology triggers regulatory queries and delays market access.
Kobalt: 99%+ consistencyRevision rate is the single most revealing quality metric. Industry average for pharmaceutical content sits between 5 and 15%. Any provider claiming zero revisions is not measuring. Ask for published, auditable numbers across a 12-month period.
Kobalt: <1% revision rateWho translates your regulatory content matters as much as how. Ask how long the same linguists have worked on pharmaceutical accounts. PM rotation every 6 to 12 months resets institutional knowledge. Regulatory precision requires years of accumulated context.
Kobalt: 14+ year client relationshipsISO 9001 and ISO 17100 are the minimum. Ask to see their quality management documentation, CAPA procedures, and how they handle non-conformances. Your regulatory auditors will want to see your translation provider's QMS. If they cannot produce it on request, they are not ready for pharma.
Kobalt: ISO 9001 + ISO 17100 certifiedAsk specifically about regulatory rejections attributable to translation. Not general quality scores or client satisfaction surveys. How many submissions have been rejected because of their translation work? Demand specifics and timeframes.
Kobalt clients: zero rejections to dateEnterprise LSPs, general translation agencies, and specialist partners approach pharmaceutical content differently. The differences show up in regulatory outcomes.
Large enterprise LSPs offer every language pair and every content type. Pharmaceutical is one vertical among dozens. Linguists are assigned by availability, not by subject-matter expertise. PM rotation means your regulatory context resets regularly. Quality relies on process scale, not domain knowledge.
Revision rates typically fall in the 5 to 15% range. Terminology databases serve all clients, not pharma specifically. Rush fees and minimum charges add up for the frequent, smaller requests common in regulatory workflows.
Mid-size agencies handle pharmaceutical content alongside marketing, legal, and technical translation. Quality varies by the individual linguist assigned. No dedicated pharmaceutical terminology management. Limited experience with regulatory submission formats and requirements.
May lack ISO 17100 certification or pharmaceutical-specific QA processes. Audit readiness is typically an afterthought. Pricing is competitive, but the cost of regulatory queries and resubmissions erodes the savings.
Dedicated pharmaceutical linguists with years of context on your products, therapeutic areas, and regulatory requirements. Terminology databases built specifically for your content. The same team handles your SmPCs, PILs, labeling, and clinical documentation across all markets.
<1% revision rate. 99%+ terminology consistency. ISO 9001 and ISO 17100 certified with audit-ready QMS documentation. Zero regulatory rejections attributable to translation for long-term clients to date.
Evaluation decisions should be based on auditable data, not sales decks. Here are published metrics from two long-term pharmaceutical client relationships.
Quiron is one of the largest healthcare groups in Europe. Kobalt has managed their multilingual regulatory and clinical content since the relationship began over 14 years ago. The same core linguistic team has worked on their account for the duration of the partnership.
Across thousands of deliverables covering patient documentation, clinical protocols, and regulatory submissions, there have been zero critical terminology errors to date. Terminology consistency remains above 99%.
14+ years 0 critical errors to date 99%+ consistencyISDIN is a global dermatology and pharmaceutical company operating across multiple regulated markets. Kobalt handles their multilingual regulatory content, including product labeling, safety documentation, and market authorization materials.
Throughout the partnership, ISDIN has experienced zero regulatory rejections attributable to translation errors to date. Every submission has passed regulatory review on the linguistic and terminological criteria.
0 rejections to date <1% revision rate Multi-market coverage*Terminology consistency measures approved-term usage in regulated content. Distinct from overall terminology accuracy (97%) across all content types.
Three phases that produce comparison data before you commit. No risk to your current operations at any point.
Select 2 to 3 representative documents from your current pipeline: an SmPC section, a PIL, and labeling content. The prospective provider translates them using your existing terminology. You compare against your current provider's output on terminology accuracy, regulatory compliance, and stylistic consistency.
The provider reviews your existing translated materials for terminology consistency, regulatory formatting compliance, and potential risk areas. This audit reveals issues your current provider may have introduced. It also demonstrates the prospective provider's depth of pharmaceutical knowledge.
Run a defined scope of live content through the new provider in parallel. Track revision rate, turnaround time, terminology consistency, and regulatory query rate. Measure the coordination time required vs. your current process. Make the transition decision based on data, not presentations.
Book a 15-minute walkthrough with real pharmaceutical examples.
Book a 15-min Regulatory Content WalkthroughAt minimum, ISO 17100 (translation services) and ISO 9001 (quality management). These certifications mean documented processes, qualified linguists, and audit trails. Ask for certificate copies and verify they cover the specific language pairs and content types you need.
Terminology consistency is measured as the percentage of approved terms used correctly across all deliverables. Industry average hovers around 85 to 90%. Kobalt maintains 99%+ consistency through dedicated terminology databases that are updated with every project and shared across all linguists working on your account.
Industry average revision rates for pharmaceutical content range from 5 to 15%. Kobalt's published revision rate is below 1%. The difference comes from subject-matter specialization, terminology management, and team continuity. The same linguists handle your content over years, not months.
Kobalt manages 80,000+ translation requests per month across multiple markets. Pharmaceutical content is high-stakes but typically lower volume than retail or e-commerce. The capacity question is about depth of expertise per language pair, not raw throughput.
A rigorous evaluation takes 4 to 8 weeks: 1 to 2 weeks for a sample translation and regulatory content audit, then 3 to 6 weeks for a pilot phase with live content. This timeline lets you compare real deliverables, not sales presentations.
Regulatory rejection due to translation errors means resubmission delays, additional regulatory fees, and potential market access delays. The cost of one rejection typically exceeds the annual difference between a specialist and generalist provider. Prevention through qualified providers is the only viable strategy.
For regulatory submissions, clinical documentation, and patient-facing materials, machine translation with post-editing introduces risk that most regulatory teams find unacceptable. For internal reference materials and non-submission content, MT+PE can work when managed by subject-matter experts who understand pharmaceutical terminology.
Start with a parallel evaluation on non-urgent content. The new provider translates the same materials as your current provider. You compare quality, terminology accuracy, and turnaround. Transition gradually, starting with content types where your current provider underperforms. At no point are you without coverage.
Send us a sample document from your current pipeline. We will show you how our pharmaceutical translation process works on your actual content, with terminology analysis and quality benchmarks.
Prefer email? ricard@kobaltlanguages.com